Navigation Links
A Handful of Pistachios a Day Helps to Keep Your Heart Healthy

When it comes to keeping your heart healthy and ticking like a well-oiled machine, all you have to do is eat a handful of pistachios every day.

The finding is based on a new research conducted by James N. Cooper M.D., of George Mason University and Michael J. Sheridan, Sc.D., of Inova Fairfax Hospital, who found that a 4-week pistachio diet, containing moderate amounts of heart healthy fat, improves risk factors for heart disease with no weight gain.

The two researchers noted that in people with moderately high cholesterol levels, a daily diet consisting of 15 percent of calories from pistachios (about two to three ounces or one to two handfuls of kernels) over a four-week period favourably improved some blood lipid levels.

The finding adds to a growing body of evidence that pistachios may offer protective benefits.

Dr Cooper said that the study also challenged the previously held belief that a low-fat diet is best for heart health.

"These results are exciting because the research indicates that adding pistachios to the daily diet can help protect the heart without a dramatic dietary lifestyle change," said Dr. James Cooper.

"This research challenges the previously-held belief that a low-fat diet is best for heart health. Studies now show that a diet with a moderate amount of healthful monounsaturated fat, like the kind found in pistachios, is a more effective way to prevent heart disease than reducing overall fat intake. What's more, we noted very good compliance and a positive response from participants during the four-week period," he said.

As a part of the study, the researchers carried out a randomised crossover trial in which 15 free-living people with moderately high blood cholesterol (greater than 210 mg/Hg) were given a diet where 15 percent of daily calories came from pistachios to see if it would have a significant impact on their blood lipid levels.
<
'"/>




Page: 1 2

Related medicine news :

1. Be True to Your Heart With a Handful of Almonds
2. Cholesterol Can Be Effectively Controlled By Sunflower Seeds, Pistachios
3. Cholesterol; Can Be Reduced By Sunflower Seeds, and Pistachios
4. Antibiotics Helps Autism
5. Serum Progesterone Helps Stratify Ectopic Pregnancy Risk
6. Prescription Drug - Helps People Stop Smoking
7. New Drug PP188 Helps Sickle Cell Disease
8. Red Wine Helps Fight Heart disease
9. Creatine Helps Strengthen Older Men
10. Cholesterol Drug Helps After Angioplasty
11. Virus Helps Remove Brain Cancer
Post Your Comments:
(Date:12/2/2008)...NGTON -- A new report from the Institute of Medici...ours and workloads to decrease the chances of fati...ning environment for these doctors in training. T...dents, work hours from the maximum average of 80 p...ate Medical Education (ACGME) in 2003, but rather ...
(Date:12/2/2008)... SAN DIEGO, Dec. 2 Stroller Stri...exercise program for new moms and their babies, ha...re for more than 40 years, has signed on as the co...ew partnership will strengthen the companies, shar.... , , "We are thrilled to have Pampers as o...
(Date:12/2/2008)... Comparator Study to Evaluate Efficacy of Commerci...WOODCLIFF LAKE, N.J., Dec. 2 Eisai... it plans to initiate the first clinical trial eva... injection) compared to Vidaza(R) (azacitidine) in...2 or high-risk myelodysplastic syndromes (MDS), a ...
(Date:12/2/2008)... Tenn., Dec. 2 Emdeon, a leading p...olutions for the healthcare industry,announced t...business,efficiency in healthcare. Emdeon unveile...ushealthcareindex.com ) to establish a national re... from a paper-based and phone-based,system to an ...
Breaking Medicine News(10 mins):Health News:Revised hours and workloads for medical residents needed to prevent 2Health News:Revised hours and workloads for medical residents needed to prevent 3Health News:Stroller Strides(R) Signs Pampers(R) as Premier Sponsor for 2009 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3Health News:Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare 2Health News:Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare 3Health News:Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare 4
...pmental Biology, members of Dr. John Herr’s labora...eport the discovery// of a new protein within a sp...contraceptive drugs. “There’s considerable intere...es,” said Herr, who heads UVa’s Center for Researc...
...Medical Center have developed the first gene chip,...diagnosis of at// least five hereditary liver dise...causes of jaundice in children and adults, and pot...nt options. The Cincinnati Children's study resul...
...ad, medical science miracles will be a fact - tech...treatments will stand to// reshape the lives of pe...planning department at Eastern Virginia Medical Sc...sh Medical Journal based on these technologies. &...
...ck pain are effective, a new review of studies has...ological outcomes such as// depression and health-...’ experience of pain. “Because this analysis was...ative than previous reviews, we have the best evid...
Other Medicine News:Health News:Male Contraception: Discovery Stirring Interest Among Scientists, Drug Developers 2Health News:First Gene Chip Discovered by Cincinnati Researchers 2Health News:First Gene Chip Discovered by Cincinnati Researchers 3Health News:Medical Science Miracles – Coming Your Wa 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 3
(Date:11/25/2008)...ss Survival of Patients Receiving Litx versus Stan...ular Carcinoma , , BELLEVUE, Wash., Nov. 25...O) today announced the completion of enrollment in... Therapy(TM) (Litx(TM)) as a treatment for unresec...s hepatoma or primary liver cancer. , , The...
(Date:11/24/2008)...ewswire/ -- Takeda Pharmaceutical Company Limited ...earch & Development Center, Inc., U.S., announ... the U.S. Food and Drug Administration (FDA) recom...eatment of hyperuricemia in patients with gout. Th...ne panel member abstaining. The vote followed pres...
(Date:11/24/2008).../ -- Leaders of Schering-Plough Corporation (NYSE:... the company,s research pipeline, highlighting a r...entities in clinical trials or under regulatory re...search and development is adding strength and brea...mation," said Fred Hassan, chairman and CEO. "Our...
(Date:11/24/2008)... long-term commitment to hepatitis research , ...ll/ -- Schering-Plough Corporation (NYSE: SGP ) ...s lead investigational oral hepatitis C protease i...company believes boceprevir has the potential to b...bitor for treating chronic hepatitis C. The compa...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 1Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 2Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 3Using DNA scientists hunt for the roots of the modern potato 2050 1Using DNA scientists hunt for the roots of the modern potato 2050 2American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 1American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 2Flextronics Announces Third Quarter Results 10427 1Flextronics Announces Third Quarter Results 10427 2Flextronics Announces Third Quarter Results 10427 3Flextronics Announces Third Quarter Results 10427 4Flextronics Announces Third Quarter Results 10427 5Flextronics Announces Third Quarter Results 10427 6Flextronics Announces Third Quarter Results 10427 7Flextronics Announces Third Quarter Results 10427 8Flextronics Announces Third Quarter Results 10427 9Flextronics Announces Third Quarter Results 10427 10Flextronics Announces Third Quarter Results 10427 11Flextronics Announces Third Quarter Results 10427 12Flextronics Announces Third Quarter Results 10427 13Flextronics Announces Third Quarter Results 10427 14Flextronics Announces Third Quarter Results 10427 15Flextronics Announces Third Quarter Results 10427 16Flextronics Announces Third Quarter Results 10427 17Flextronics Announces Third Quarter Results 10427 18Flextronics Announces Third Quarter Results 10427 19
...Calif., June 05, 2007 /PRNewswire/ -- MAP,Pharmace... Phase 2,data from its MAP0004 migraine therapy cl...e Society Meeting at the Hyatt Regency,Chicago in ...was,accepted as a late-breaker, is entitled Rapid ...led Dihydroergotamine Mesylate,via a Novel Inhaler...
...une 05, 2007 /PRNewswire/ -- , Professor Home said...ppointing and,misleading in that they disregarded ...nt to patients and physicians. Most,significantly ...e,of any increase in cardiovascular death or death...T: Professor Philip Home, (44) 778-525-1736 , Ter...
Other Medicine Technology:MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the,American Headache Society Meeting 2
...oped a range of Milli-Q ultrapure water systems de...s. Each of the five new Milli-Q systems is designe...to particular applications such as HPLC, molecular...h precision resistivity monitor that records condu...
...oped a range of Milli-Q ultrapure water systems de...s. Each of the five new Milli-Q systems is designe...to particular applications such as HPLC, molecular...h precision resistivity monitor that records condu...
...oped a range of Milli-Q ultrapure water systems de...s. Each of the five new Milli-Q systems is designe...to particular applications such as HPLC, molecular...h precision resistivity monitor that records condu...
...oped a range of Milli-Q ultrapure water systems de...s. Each of the five new Milli-Q systems is designe...to particular applications such as HPLC, molecular...h precision resistivity monitor that records condu...
Medicine Products: